Eli Lilly has just signed a $2.75 billion contract with Insilico Medicine.
This deal is more significant than the headline figure suggests. It is not Lilly buying another AI server or signing another computing contract with NVIDIA. This time, Lilly is purchasing the drugs that Insilico designed using AI.
What the Money Buys
The contract structure: $150 million upfront, with the remaining approximately $600 million paid in milestone-based installments, plus royalties on sales.
Lilly obtains global exclusive licenses for a batch of oral small-molecule drug candidates from Insilico, covering development, manufacturing, and commercialization rights. The candidates span multiple therapeutic areas, though not all specific targets have been disclosed. However, sources indicate that one of them is a GLP-1 candidate, the core therapeutic area of Lilly's Mounjaro (tirzepatide).
This is about buying existing drugs, not buying tools.
This distinction is crucial. In recent years, most collaborations between big pharma and AI companies have followed this pattern: I pay you, you run virtual screening for me, you help me find targets faster. AI is the tool; the drug is still designed by humans.
What Insilico is selling to Lilly are molecules designed entirely by AI from start to finish: targets identified by AI, molecular structures generated by AI, and clinical performance predicted by AI. Lilly's role is to advance these drug candidates into clinical trials.
How Insilico's Platform Works
Insilico Medicine is a Hong Kong-based company led by CEO Alex Zhavoronkov. Its core product is Pharma.AI, an end-to-end AI drug discovery platform comprising three modules:
| Module | Function |
|---|---|
| PandaOmics | Disease target identification |
| Chemistry42 | AI generation of novel molecular structures |
| inClinico | Clinical trial outcome prediction |
The entire process is handled by AI, from determining the key targets of a disease to predicting how a molecule will behave in the human body.
To date, Insilico has designed 28 drug candidates using this platform, with nearly half already in clinical stages.
The most representative example is ISM001-055, a drug for idiopathic pulmonary fibrosis (IPF). It is the world's first drug fully discovered and designed by AI to advance to Phase II clinical trials. From target discovery to clinical candidate confirmation, it took only 18 months, compared to the typical 4-6 years using traditional methods.
Why Lilly Signed This Contract
Lilly is now one of the world's most valuable pharmaceutical companies, but it is well aware that the patent window for glucagon-like peptide-1 (GLP-1) is not permanent. It needs its next generation of products.
Insilico's AI platform can theoretically rapidly generate a large number of diverse candidate molecules, particularly oral small molecules. If one of them enters Lilly's GLP-1 follow-up pipeline, its value could far exceed the $2.75 billion milestone total.
Zhavoronkov called Lilly the best partner for these drug candidates, which may sound like a courtesy, but Lilly's clinical development capabilities in metabolic diseases are indeed unmatched.
Industry Significance
The pharmaceutical industry has been talking about AI for a decade, with most stories stopping at "we are using AI to assist R&D."
This time is different: A top-tier pharma company is willing to put real money on the line for molecules designed by AI, and is betting on their commercialization rights.
Previously, Lilly had signed an AI computing collaboration with NVIDIA, but that was infrastructure. This Insilico contract treats AI as a source of new drugs, not just a research tool.
The difference is like buying a faster microscope versus buying what the microscope discovered.
If Lilly can advance these drug candidates to Phase III trials and market approval, and Insilico receives the full milestone payments, this deal could rewrite the valuation logic for AI drugs in the pharmaceutical industry.
What Remains to Be Seen
Drug candidates only truly succeed when they pass clinical trials. The $150 million is money Lilly has already paid; the remaining $600 million depends on the candidates clearing each hurdle.
Insilico's first star drug, ISM001-055, is still awaiting Phase II clinical data. If problems arise, the entire AI drug discovery narrative will face renewed skepticism.
But the fact that Lilly was willing to sign this contract at this point in time already speaks volumes.
Sources: Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market (CNBC); AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion (STAT News); Insilico Shares Surge on AI Drug Development Deal with Eli Lilly (Bloomberg); CocoLoop, Lilly's AI commitment expands through deal with Insilico (BioPharma Dive)